Study summary

Aficamten became the first myosin inhibitor to help nonobstructive HCM

ACACIA-HCM trial · About 516 people, phase 3 · Topline May 2026; presented at ESC 2026 and published in NEJM

What was tested

Aficamten against placebo for symptomatic nonobstructive hypertrophic cardiomyopathy.

What they found

• Met both primary goals, improving symptoms (KCCQ) and peak oxygen uptake.
• Ejection fraction fell below 50% more often (10% vs 1%), managed by dose adjustment.

What it means

Could give the roughly half of HCM patients with nonobstructive disease their first approved drug.